Comparison
Dulaglutide vs. Maridebart Cafraglutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
923950-08-7
no data
Molecular weight
59670 g/mol
no data
Half-life
110 h
no data
Sequence
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fcno data
Mechanism of action
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Maridebart Cafraglutide
MariTide combines GLP-1 receptor agonism with GIP receptor antagonism in an antibody-peptide conjugate. Its long duration of action allows infrequent (monthly) dosing.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
5
1
of which in humans
5
1
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Dulaglutide and Maridebart Cafraglutide?
- Dulaglutide is classified as "Metabolic", while Maridebart Cafraglutide is classified as "Metabolic". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Maridebart Cafraglutide: Maridebart cafraglutide (MariTide, Amgen) is a bispecific molecule: a GLP-1 receptor agonist combined with a GIP receptor antagonist, designed for monthly dosing; in phase 3 for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Maridebart Cafraglutide?
- The highest available evidence level is "Human RCT" for Dulaglutide and "Human RCT" for Maridebart Cafraglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Maridebart Cafraglutide in Germany and the United States?
- Germany: Dulaglutide — Prescription, Maridebart Cafraglutide — Unapproved. United States: Dulaglutide — Prescription, Maridebart Cafraglutide — Unapproved. These are factual summaries with source and review date on the individual pages.